This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
SMARCAD1 / SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily A containing DEAD/H box 1 · IHC design guide
Design Immunohistochemistry for SMARCAD1
Plan SMARCAD1 paraffin IHC around general nuclear staining (HPA tissue IHC). Start the catalog antibody at 0.5–1 μg/mL (datasheet A06049-1) and score nuclear signal against matched controls (standard IHC practice).
Evidence assembled Oct 2026 · For research use; verify linked source records and product datasheet before use
SMARCAD1 Immunohistochemistry Experimental Design Guide
Expected localisation, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before staining
| Expected localisation | General nuclear tissue staining (HPA tissue IHC) | |
| Staining pattern | Nuclear staining across many cell types (HPA tissue IHC) | |
| Antigen retrieval | Citrate pH 6 HIER, heat-mediated (datasheet A06049-1) | |
| Positive control | Adrenal gland+4 more · see all | |
| Negative control | Liver |
Important caveats
Reasons your staining may differ from the expected pattern.
| Fixation | Keep fixation consistent across sections (standard IHC practice; not target-specific) | |
| Caveat | Antibody staining and RNA show medium consistency (HPA tissue IHC) | |
| Regulation | Isoform 3 mainly in skin and esophagus (UniProt) | |
| Isoform / epitope | 3 isoforms; verify epitope coverage (UniProt) |
Section 1
Recommended SMARCAD1 IHC & IF Protocols
Compare the catalog antibody’s IHC-P protocol (datasheet: A06049-1) with the published SMARCAD1 brain-section protocol (PMC13240146).
| Sample | Paraffin-embedded human colon cancer tissues; fixative not specified (datasheet A06049-1) |
| Fixation | Image fixative and duration unreported (datasheet A06049-1); verify before use. |
| Sectioning | 4–5 µm sections on charged slides (standard) |
| Deparaffinisation | Xylene, graded ethanol series to water (standard) |
| Antigen retrieval | Heat retrieval: Citrate pH 6, 20 min (datasheet A06049-1) |
| Peroxidase block | 3% H2O2, 10 min, room temperature (standard) |
| Blocking | 10% goat serum (datasheet A06049-1) |
| Primary antibody | Rabbit anti-SMARCAD1, 0.5-1μg/ml (datasheet A06049-1) |
| Primary incubation | Overnight at 4 °C (datasheet A06049-1) |
| Detection | Streptavidin-biotin complex (SABC), DAB chromogen (datasheet A06049-1) |
| Counterstain | Hematoxylin, blue, dehydrate and mount (standard) |
| Expected result | SMARCAD1-positive staining in glandular cells of adrenal gland (HPA tissue IHC: High). HPA tissue profile: General nuclear expression. No signal in the no-primary control. |
💡Decision noteStart with heat-mediated citrate pH 6 retrieval (datasheet: A06049-1); the published brain-section method used an autoclave with citrate buffer (PMC13240146).
Section 2
What Is the Expected SMARCAD1 Staining Pattern?
SMARCAD1 is a nuclear chromatin regulator with no transmembrane segment (UniProt Q9H4L7: location and topology). In paraffin sections, expect predominantly nuclear staining across multiple cell types (HPA tissue IHC: general nuclear expression; low tissue specificity). The tissue IHC profile is Approved, with medium consistency between antibody staining and RNA expression (HPA tissue IHC: reliability).
| Distinct nuclear chromogen in breast or duodenal glandular cells, or bone marrow hematopoietic cells. | This fits reported High staining in those cells (HPA tissue IHC: breast, duodenum, bone marrow). Interpret the signal by cell and compartment; general nuclear expression does not imply equal intensity in every tissue (HPA tissue IHC: profile and levels). |
| Predominantly cytoplasmic or membrane-associated signal, with little nuclear signal. | This conflicts with the expected nuclear pattern (HPA tissue IHC: general nuclear expression; UniProt Q9H4L7: nucleus and chromosome). Review localisation against a nuclear counterstain, then check detection background and antibody specificity (general IHC practice). |
| Strong staining in liver cholangiocytes while known-positive cells stain as expected. | Cholangiocytes are reported Not detected, so this result warrants investigation for cross-reactivity or endogenous detection activity (HPA tissue IHC: liver cholangiocytes; general IHC practice). The finding does not establish that all liver cells should be negative. |
| Diffuse chromogen over nuclei, cytoplasm and tissue spaces. | A widespread deposit obscures the compartment needed to call SMARCAD1 positive (HPA tissue IHC: general nuclear expression). Check background with an appropriate negative control and review blocking, antibody concentration and detection steps (general IHC practice). |
| No nuclear signal in a section containing reported High-staining cells. | Absence of signal in those cells weakens a negative interpretation (HPA tissue IHC: High in breast glandular cells and bone marrow hematopoietic cells). Check section quality, retrieval, antibody and detection performance with a known-positive control (general IHC practice). |
💡Expected SMARCAD1 appearanceCall a convincing positive when chromogen is predominantly nuclear in reported High-staining cells, such as breast glandular cells; strong cytoplasmic staining alone is suspect (HPA tissue IHC: breast and general nuclear expression).
| Tissue and cell selection | HPA reports High staining in adrenal and appendix glandular cells, cerebellar Purkinje cells, cerebral cortex glial cells and colon endothelial cells; heart cardiomyocytes are Low (HPA tissue IHC: cell-level observations). Compare the same cell types when judging intensity. |
| Isoform distribution | Isoform 1 is ubiquitous, while isoform 3 is mainly expressed in skin and esophagus (UniProt Q9H4L7: tissue specificity). The supplied record does not establish which isoforms the IHC antibody detects, so isoform distribution alone cannot predict staining intensity. |
| Target location and epitope scope | SMARCAD1 has no transmembrane segment or signal peptide and is annotated in the nucleus and chromosome (UniProt Q9H4L7: topology, processing and location). The antibody epitope is unspecified here; these annotations do not establish retrieval needs or fixation sensitivity. |
| IF/ICC Q&A: where should the signal appear? | Predominantly in the nucleoplasm (HPA subcellular ICC-IF: enhanced nucleoplasm; HPA antibody HPA016737: ICC Enhanced). This supports a localisation cross-check; ICC validation does not set an IHC staining intensity or provide an IF protocol. |
| Situation | Likely cause | Next action |
|---|---|---|
| Reported High-staining cells have no nuclear signal. | The IHC run may have failed, or the sampled section may lack the expected cell population (HPA tissue IHC: cell-level High observations; general IHC practice). | Confirm cell identity and section quality, then review retrieval and detection against a known-positive section (general IHC practice). No SMARCAD1-specific retrieval condition is established by the supplied sources. |
| Cytoplasmic staining dominates the slide. | The distribution disagrees with nuclear SMARCAD1 localisation and may reflect nonspecific signal (HPA tissue IHC: general nuclear expression; UniProt Q9H4L7: nucleus; general IHC practice). | Use a nuclear counterstain to check compartment boundaries, inspect a negative control, and reassess antibody concentration and detection background (general IHC practice). |
| Liver cholangiocytes show strong staining. | This differs from the reported Not detected result; cross-reactivity or endogenous detection activity is possible (HPA tissue IHC: liver cholangiocytes; general IHC practice). | Confirm the stained cells are cholangiocytes, inspect the negative control and endogenous-activity blocking, and compare with reported High-staining cells (general IHC practice; HPA tissue IHC: cell-level observations). |
| Chromogen is diffuse or covers tissue spaces. | Background deposition can make nuclear localisation unreadable (general IHC practice; HPA tissue IHC: general nuclear expression). | Compare a negative control and review blocking, washes, antibody concentration and detection timing (general IHC practice). Score only cells whose nuclear signal can be distinguished from background. |
| Cardiomyocytes stain weakly beside stronger cells. | Low staining is reported for heart muscle cardiomyocytes (HPA tissue IHC: heart muscle). Weak signal there alone does not show that the IHC run failed. | Assess nuclear localisation and background, then use a reported High-staining cell population to check run performance (HPA tissue IHC: general nuclear expression and cell-level observations; general IHC practice). |
| IHC and IF/ICC images seem to show different compartments. | HPA describes general nuclear tissue IHC and enhanced nucleoplasmic ICC-IF localisation; section and cell-image appearances may differ (HPA tissue IHC: profile; HPA subcellular ICC-IF: main location). | Compare nuclear boundaries and controls within each application before interpreting a discrepancy (general IHC/IF practice). Treat the ICC-IF result as a localisation reference, not an IHC intensity standard. |
Experiment evidence
IHC & IF images showing SMARCAD1 staining
A06049-1 · IHCIHC analysis of SMARCAD1 using anti-SMARCAD1 antibody (A06049-1). SMARCAD1 was detected in paraffin-embedded section of human colon cancer t
A06049-1 · IHCIHC analysis of SMARCAD1 using anti-SMARCAD1 antibody (A06049-1). SMARCAD1 was detected in paraffin-embedded section of human mammary cancer
A06049-1 · IFIF analysis of SMARCAD1 using anti-SMARCAD1 antibody (A06049-1). SMARCAD1 was detected in immunocytochemical section of A431 cells. Enzyme a
HPA · Cerebral cortexHuman Protein Atlas IHC, Cerebral cortex. Source: https://www.proteinatlas.org/ENSG00000163104-SMARCAD1/tissue/cerebral+cortex#imid_4493092
HPA · EsophagusHuman Protein Atlas IHC, Esophagus. Source: https://www.proteinatlas.org/ENSG00000163104-SMARCAD1/tissue/esophagus#imid_4493056
HPA · ColonHuman Protein Atlas IHC, Colon. Source: https://www.proteinatlas.org/ENSG00000163104-SMARCAD1/tissue/colon#imid_4493010
HPA · LiverHuman Protein Atlas IHC, Liver. Source: https://www.proteinatlas.org/ENSG00000163104-SMARCAD1/tissue/liver#imid_4493019
HPA · ICC-IF A-431Human Protein Atlas immunofluorescence, A-431, antibody HPA016737; green = SMARCAD1, blue = nucleus, red = microtubules.
HPA · ICC-IF A-431Human Protein Atlas immunofluorescence, A-431, antibody HPA016737; green = SMARCAD1, blue = nucleus, red = microtubules.
← swipe / scroll for more images →
Real IHC / IF data behind the staining-pattern expectations in this section.
Sample controls for SMARCAD1 IHC & IF
🧪Run adrenal gland first: its glandular cells should show nuclear staining (HPA: High in adrenal gland glandular cells; UniProt Q9H4L7: nucleus). Use liver cholangiocytes as the negative tissue (HPA: Not detected in liver cholangiocytes); any independently verified unstained cells on the adrenal slide should show background only, without nuclear DAB signal.
Positive control tissue: Adrenal gland (Glandular cells, HPA High)
Negative control tissue: Liver (HPA Not detected)
ICC-IF cell lines (HPA subcellular resource): HPA ICC-IF images show SMARCAD1 in A-431, U-251MG, U2OS, U2OS, siRNA 1 (10x), U2OS, siRNA 1 (40x), U2OS, siRNA 2 (10x), U2OS, siRNA 2 (40x), U2OS, scrambled (10x), U2OS, scrambled (40x), with annotated localisation: Nucleoplasm (enhanced) (HPA subcellular).
Technical controls: Include a no-primary, secondary-only control, a rabbit IgG isotype control matched to the primary antibody’s clonality, and a SMARCAD1 knockout biological control where available (caption: rabbit primary; standard IHC practice). Block endogenous peroxidase and check for endogenous biotin when using the caption’s biotin-based DAB detection (caption: biotinylated secondary, streptavidin–biotin complex and DAB; standard IHC practice).
⚠️Feasibility: The selected A06049-1 paraffin-section caption reports citrate retrieval at pH 6 for 20 minutes, but reports neither the fixative nor a target-specific fixation window or fixation effect (A06049-1 tissue-IHC caption). That caption supports testing the stated retrieval conditions; the supplied evidence does not establish whether frozen sections or IF are easier (A06049-1 tissue-IHC caption; HPA: ICC-IF nucleoplasm images). Assess adrenal background carefully with the biotin-based DAB system (caption: streptavidin–biotin complex and DAB; standard IHC practice).
HPA tissue IHC evidence for SMARCAD1
Comprehensive Human Protein Atlas IHC scoring per tissue (reliability: Approved — Medium consistency between antibody staining and RNA expression data.). Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Adrenal gland | Glandular cells | High | Protein (IHC) | HPA → |
| Appendix | Glandular cells | High | Protein (IHC) | HPA → |
| Bone marrow | Hematopoietic cells | High | Protein (IHC) | HPA → |
| Breast | Glandular cells | High | Protein (IHC) | HPA → |
| Cerebellum | Purkinje cells | High | Protein (IHC) | HPA → |
Undetected expression · recommended negative controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Liver | Cholangiocytes | Not detected | Protein (IHC) | HPA → |
Section 3
Advanced SMARCAD1 IHC Tips
Troubleshoot SMARCAD1 staining by checking nuclear localisation, retrieval conditions, cell type and controls before comparing signal intensity across sections.
What retrieval conditions should I try when nuclear SMARCAD1 staining is weak?
Start with heat-mediated retrieval in citrate buffer at pH 6 (datasheet A06049-1). The catalog antibody’s paraffin-section example heated sections for 20 minutes, then used 1 μg/ml primary antibody overnight at 4°C (IHC caption A06049-1). If nuclear staining remains weak, compare a modestly longer citrate heating step with the original condition on matched sections, keeping detection and exposure to chromogen constant (standard IHC practice). Include a known staining reference and a no-primary control in each comparison (standard IHC practice). Judge improvement by clearer nuclear signal without increased diffuse background, because SMARCAD1 is nuclear and chromosomal (UniProt Q9H4L7).
Could fixation explain weak or uneven SMARCAD1 staining in paraffin sections?
Target-specific fixation sensitivity is unknown: the catalog’s paraffin-section caption does not state a fixative (IHC caption A06049-1). Record the fixative, fixation duration and processing history for each section, then compare matched sections processed together (standard IHC practice). Keep citrate retrieval at pH 6 for 20 minutes as a documented starting condition while investigating processing differences (datasheet A06049-1; IHC caption A06049-1). Assess intact nuclei away from folds and section edges, and use a no-primary control to check nonspecific deposit (standard IHC practice). Neither the reported nuclear distribution nor the protein’s modifications establish a particular fixation effect (HPA tissue IHC; UniProt Q9H4L7).
How should I evaluate cytoplasmic or patchy staining when SMARCAD1 is expected in nuclei?
Prioritise nuclear staining: SMARCAD1 is reported in the nucleus and on chromosomes, and HPA describes general nuclear tissue expression (UniProt Q9H4L7; HPA tissue IHC). HPA further places its enhanced subcellular signal in the nucleoplasm (HPA subcellular). Compare stained nuclei with the counterstain at the same magnification, and score cytoplasmic deposit separately rather than adding it to nuclear positivity (standard IHC practice). A patchy pattern can reflect the sampled cell population, so compare like cells across sections; HPA reports high staining in colon endothelial cells and no detection in liver cholangiocytes (HPA tissue IHC). Verify unexpected cytoplasmic signal with a no-primary control and an independent staining assessment (standard IHC practice).
Can this antibody distinguish SMARCAD1 isoforms or modification-dependent staining?
The record lists 3 SMARCAD1 isoforms, but the supplied catalog caption does not identify the antibody epitope (UniProt Q9H4L7; IHC caption A06049-1). Therefore, do not assign staining to one isoform without an epitope map and independent validation (standard IHC practice). Isoform 1 is described as ubiquitous, whereas isoform 3 is mainly expressed in skin and esophagus; those distributions alone cannot establish antibody selectivity (UniProt Q9H4L7). The protein also has reported modified residues, including phosphorylation at positions 39, 54 and 57 (UniProt Q9H4L7). If staining changes across samples, assess retrieval and specimen quality before attributing that change to isoform abundance or epitope modification (standard IHC practice).
How can IF help resolve uncertain cell identity or nuclear localisation?
Use this page’s chromogenic IHC result as the starting observation, then assess localisation with a separate IF assay (standard IHC/IF practice). For multiplex IF, pair SMARCAD1 with a validated marker of the cell type being assessed, such as an endothelial marker when examining colon endothelium, where HPA reports high staining (HPA tissue IHC; standard IF practice). Choose a fluorophore channel with low tissue autofluorescence, often a far-red channel, and include single-channel controls for spectral bleed-through (standard IF practice). Because the expected epitope is intracellular and the protein lacks a transmembrane segment, test permeabilisation that permits nuclear access (UniProt Q9H4L7; standard IF practice). Compare the signal with a nuclear counterstain; HPA reports nucleoplasmic localisation (HPA subcellular).
What should I check when DAB staining obscures SMARCAD1-positive nuclei?
First inspect a no-primary section to distinguish detection-system deposit from primary-dependent staining (standard IHC practice). The catalog example used 10% goat serum blocking, a biotinylated secondary, a streptavidin–biotin complex and DAB (IHC caption A06049-1). With that detection chemistry, check endogenous peroxidase blocking and assess whether endogenous biotin contributes signal; these are general IHC controls, not demonstrated SMARCAD1-specific effects (standard IHC practice). Titrate primary antibody around the documented 1 μg/ml condition and keep DAB development consistent across comparisons (IHC caption A06049-1; standard IHC practice). Treat diffuse cytoplasmic or tissue-edge colour cautiously because the expected signal is nuclear (UniProt Q9H4L7; standard IHC practice).
How should I score SMARCAD1 staining across sections with different cell mixtures? ⚠ ANSWER MARKED FOR VERIFICATION
Define the cell population and count evaluable nuclei before comparing sections, because HPA reports different staining levels among cell types (HPA tissue IHC; standard IHC practice). Record the percentage of positive nuclei and an intensity score, then calculate a nuclear H-score on a 0–300 scale if intensity categories are reproducible (standard IHC practice). For spatial questions, report positive nuclei per mm² within a specified tissue compartment (standard IHC practice). Normalise each result to the number of evaluable nuclei or measured compartment area, and exclude necrosis, folds and poorly preserved regions consistently (standard IHC practice). Keep retrieval, antibody concentration, imaging and scoring thresholds matched; the catalog example used 1 μg/ml primary antibody (IHC caption A06049-1; standard IHC practice).
When does an unusual staining pattern warrant a specificity check?
A credible SMARCAD1 signal should align with nuclei, since UniProt places the protein in nuclei and on chromosomes and HPA reports nucleoplasmic localisation (UniProt Q9H4L7; HPA subcellular). Compare the same cell type in intact regions, rather than treating every stained structure as equivalent; HPA reports high staining in colon endothelial cells and no detection in liver cholangiocytes (HPA tissue IHC). Question staining concentrated at cut edges, within necrotic areas or outside nuclei, and check the corresponding no-primary section for deposit (standard IHC practice). Because the catalog example uses DAB with a streptavidin–biotin detection system, assess endogenous peroxidase and biotin when unexpected colour persists (IHC caption A06049-1; standard IHC practice). Interpret apparent damage-associated foci cautiously: SMARCAD1 is recruited to double-strand breaks, but chromogenic staining alone does not establish DNA damage (UniProt Q9H4L7; standard IHC practice).
Boster reagents
Best SMARCAD1 / SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily A containing DEAD/H box 1 IHC Antibodies
The catalog antibody A06049-1 has IHC images from paraffin-embedded human colon and mammary cancers and mouse and rat brain, plus an IF/ICC image from A431 cells (catalog image captions).
Real IHC data
Anti-SMARCAD1 Antibody ®
Cat # A06049-1
A06049-1 will render with its human colon cancer IHC figure (catalog IHC figure caption). Its other IHC captions show human mammary cancer and mouse and rat brain; its IF/ICC caption shows A431 cells (catalog image captions).
Which to pick: Choose A06049-1 for paraffin-section IHC: its own IHC captions document those sections, while the fixative is unreported (catalog IHC image captions). The same SKU covers IF/ICC in A431 cells and lists human, mouse and rat reactivity (catalog IF image caption; catalog applications and reactivity). Clonality is unreported (catalog clone field).
Each figure is that product's own IHC / IF validation image from its datasheet.
References
- UniProt Consortium. UniProt entry Q9H4L7 (SMRCD_HUMAN, SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily A containing DEAD/H box 1).
- Human Protein Atlas. SMARCAD1 tissue IHC expression (reliability: Approved).
- Human Protein Atlas. SMARCAD1 subcellular location (ICC-IF): Localized to the nucleoplasm..
- Human Protein Atlas. SMARCAD1 antibody validation summary (1 antibodies).
- Wybutosine hypomodification of tRNAphe activates HERVK and impairs neuronal differentiation. iScience 2024 — PMC11066470.
- Loss of SMARCAD1 Mitigates Tauopathy. Aging cell 2026 — PMC13240146.
- SMARCAD1 Promotes Pancreatic Cancer Cell Growth and Metastasis through Wnt/β-catenin-Mediated EMT. International journal of biological sciences 2019 — PMC6367592.
- PubMed PMID:11031099 — UniProt-cited evidence.
- PubMed PMID:10574461 — UniProt-cited evidence.
- PubMed PMID:14702039 — UniProt-cited evidence.
Immunohistochemistry protocol sheet for SMARCAD1 (SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily A containing DEAD/H box 1). Expected localisation General nuclear tissue staining (HPA tissue IHC). Antigen retrieval: Citrate pH 6 HIER, heat-mediated (datasheet A06049-1). Validated IHC antibody: A06049-1 at 0.5-1μg/ml (the product's own IHC validation image is shown). Controls (HPA): positive Adrenal gland (Glandular cells); negative Liver. IHC-P workflow on paraffin sections; fixative unspecified. Protocol steps: 1. Sample: Paraffin-embedded human colon cancer tissues; fixative not specified (datasheet A06049-1); 2. Fixation: Image fixative and duration unreported (datasheet A06049-1); verify before use.; 3. Sectioning: 4–5 µm sections on charged slides (standard); 4. Deparaffinisation: Xylene, graded ethanol series to water (standard); 5. Antigen retrieval: Heat retrieval: Citrate pH 6 , 20 min (datasheet A06049-1); 6. Peroxidase block: 3% H2O2, 10 min , room temperature (standard); 7. Blocking: 10% goat serum (datasheet A06049-1); 8. Primary antibody: Rabbit anti-SMARCAD1, 0.5-1μg/ml (datasheet A06049-1); 9. Primary incubation: Overnight at 4 °C (datasheet A06049-1). Watch for: Fixation: Keep fixation consistent across sections (standard IHC practice; not target-specific); Caveat: Antibody staining and RNA show medium consistency (HPA tissue IHC); Isoform / epitope: 3 isoforms; verify epitope coverage (UniProt); Regulation: Isoform 3 mainly in skin and esophagus (UniProt). Evidence: UniProt Q9H4L7, HPA tissue IHC · Approved, HPA ICC-IF · nucleoplasm., Datasheet A06049-1, PMC13240146. QR code links to https://www.bosterbio.com/bosterbio-gene-info-cards/SMARCAD1/immunohistochemistry-ihc-guide.